DYNABAC Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Dynabac, and when can generic versions of Dynabac launch?
Dynabac is a drug marketed by Lilly Res Labs and is included in one NDA.
The generic ingredient in DYNABAC is dirithromycin. There is one drug master file entry for this compound. Additional details are available on the dirithromycin profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for DYNABAC?
- What are the global sales for DYNABAC?
- What is Average Wholesale Price for DYNABAC?
Summary for DYNABAC
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 45 |
| Clinical Trials: | 4 |
| Patent Applications: | 229 |
| DailyMed Link: | DYNABAC at DailyMed |
Recent Clinical Trials for DYNABAC
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Pharmaceutical Research Unit, Jordan | Phase 1 |
| Abdi Ibrahim Ilac San. ve Tic A.S. | Phase 1 |
US Patents and Regulatory Information for DYNABAC
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lilly Res Labs | DYNABAC | dirithromycin | TABLET, DELAYED RELEASE;ORAL | 050678-001 | Jun 19, 1995 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
